Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 901–1,000 of 1,012
Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
Lallous, N., Dalal, K., Cherkasov, A. R., & Rennie, P. S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140612496 · Cited by 79
“structures [108–110].”
Tohyama, S., Miyagawa, S., Lange, A., Ogino, Y., Mizutani, T., Tatarazako, N., Katsu, Y., Ihara, M., Tanaka, H., Ishibashi, H., et al. (2015) · Environmental Science & Technology · doi:10.1021/acs.est.5b00704 · Cited by 79
Swinney, D. C. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256679 · Cited by 79
Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study
Kao, Y., Korzekwa, K. R., Laughton, C. A., & Chen, S. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2001.01886.x · Cited by 79
Bachmann, C. G., Linthorst, A. C. E., Holsboer, F., & Reul, J. M. H. M. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300158 · Cited by 81
The Rexinoid LG100754 Is a Novel RXR:PPARγ Agonist and Decreases Glucose Levels in Vivo
Cesario, R. M., Klausing, K., Razzaghi, H., Crombie, D., Rungta, D., Heyman, R. A., & Lala, D. S. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.8.0677 · Cited by 71
Building Transcriptional Regulatory Complexes: Signals and Surfaces
YAMAMOTO, K. R., DARIMONT, B. D., WAGNER, R. L., & INIGUEZ-LLUHI, J. A. (1998) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1998.63.587 · Cited by 73
Riby, J. E., Feng, C., Chang, Y., Schaldach, C., Firestone, G. L., & Bjeldanes, L. F. (2000) · Biochemistry · doi:10.1021/bi9919706 · Cited by 79
Role of astroglia in the neuroplastic and neuroprotective actions of estradiol
Azcoitia, Í., Santos‐Galindo, M., Arévalo, M., & García‐Segura, L. M. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07516.x · Cited by 78
“, 1999), which is modified by SERMs (Brzozowski et al., 1997; Paige et al., 1999).”
BackgroundZhou, H., Nettles, K. W., Bruning, J. B., Kim, Y., Joachimiak, A., Sharma, S., Carlson, K. E., Stossi, F., Katzenellenbogen, B. S., Greene, G. L., et al. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.04.009 · Cited by 78
Self-citationTop, S., Vessières, A., Pigeon, P., Rager, M., Huché, M., Salomon, E., Cabestaing, C., Vaissermann, J., & Jaouen, G. (2004) · ChemBioChem · doi:10.1002/cbic.200400067 · Cited by 78
Overview of the structural basis for transcription regulation by nuclear hormone receptors
Kumar, R., Johnson, B. H., & Thompson, E. B. (2004) · Essays in Biochemistry · doi:10.1042/bse0400027 · Cited by 65
“At least some ligands that act as antagonists appear to cause altered movement of H12 to a position that creates an unfavourable surface for co-activator binding [14].”
BackgroundAyoub, N. M., Siddique, A. B., Ebrahim, H. Y., Mohyeldin, M. M., & Sayed, K. A. E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.06.019 · Cited by 78
Frkic, R. L., Marshall, A. C., Blayo, A., Pukala, T. L., Kamenecka, T. M., Griffin, P. R., & Bruning, J. B. (2018) · iScience · doi:10.1016/j.isci.2018.06.012 · Cited by 78
Ghosh, U., Ganessunker, D., Sattigeri, V. J., Carlson, K. E., Mortensen, D. S., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00309-7 · Cited by 78
Fokialakis, N., Lambrinidis, G., Mitsiou, D. J., Aligiannis, N., Mitakou, S., Skaltsounis, A., Pratsinis, H., Mikros, E., & Alexis, Μ. N. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.014 · Cited by 79
X-ray crystallographic and functional studies of thyroid hormone receptor
Ribeiro, R. C. J., Apriletti, J. W., Wagner, R., Feng, W., Kushner, P. J., Nilsson, S. V., Scanlan, T. S., West, B. L., Fletterick, R. J., & Baxter, J. D. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00029-6 · Cited by 78
Estrogen Receptor α Inhibits IL-1β Induction of Gene Expression in the Mouse Liver
Evans, M. J., Lai, K., Shaw, L. J., Harnish, D. C., & Chadwick, C. C. (2002) · Endocrinology · doi:10.1210/endo.143.7.8919 · Cited by 69
In silico tools to aid risk assessment of endocrine disrupting chemicals
Jacobs, M. N. (2004) · Toxicology · doi:10.1016/j.tox.2004.06.036 · Cited by 78
Schreurs, R. H. M. M., Quaedackers, M. E., Seinen, W., & van der Burg, B. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9458 · Cited by 78
Perspective: Female Steroid Hormone Action
Conneely, O. M. (2001) · Endocrinology · doi:10.1210/endo.142.6.8288 · Cited by 79
Three-dimensional modeling of and ligand docking to vitamin D receptor ligand binding domain
Yamamoto, K., Masuno, H., Choi, M., Nakashima, K., Taga, T., Ooizumi, H., Umesono, K., Sicińska, W., Vanhooke, J. L., DeLuca, H. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.020522697 · Cited by 78
Potential tissue selectivity of dietary phytoestrogens and estrogens
Cassidy, A. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199902000-00009 · Cited by 78
Masood, D.-E.-N., Roach, E. C., Beauregard, K. G., & Khalil, R. A. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233477 · Cited by 78
“Park WC, Jordan VC. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.”
BackgroundInfluentialVirtual Screening in the Cloud: How Big Is Big Enough?
Grebner, C., Malmerberg, E., Shewmaker, A., Batista, J., Nicholls, A., & Sadowski, J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00779 · Cited by 72
Shi, R., & Lin, S.-X. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313156200 · Cited by 76
An Extended LXXLL Motif Sequence Determines the Nuclear Receptor Binding Specificity of TRAP220
Coulthard, V. H., Matsuda, S., & Heery, D. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212950200 · Cited by 77
Nakabayashi, M., Yamada, S., Yoshimoto, N., Tanaka, T., Igarashi, M., Ikura, T., Ito, N., Makishima, M., Tokiwa, H., DeLuca, H. F., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8004477 · Cited by 76
Virtual screening: An in silico tool for interlacing the chemical universe with the proteome
Westermaier, Y., Barril, X., & Scapozza, L. (2014) · Methods · doi:10.1016/j.ymeth.2014.08.001 · Cited by 76
Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
Bafna, D., Ban, F., Rennie, P. S., Singh, K., & Cherkasov, A. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124193 · Cited by 77
“H11 is also important because it contains the nuclear localization signal [94].”
BackgroundMethodInfluentialKörner, W., Vinggaard, A. M., Térouanne, B., Ma, R., Wieloch, C., Schlumpf, M., Sultan, C., & Soto, A. M. (2004) · Environmental Health Perspectives · doi:10.1289/ehp.112-1241964 · Cited by 76
“The elucidation of the crystal structure of the ligand-binding domain of the human estrogen receptor (ER)-α (Brzozowski et al. 1997) explained, in part, this surprising structural diversity.”
BackgroundSelective Estrogen Receptor Modulators: Tissue Actions and Potential for CNS Protection
Littleton‐Kearney, M. T., Ostrowski, N. L., Cox, D. A., Rossberg, M. I., & Hurn, P. D. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00230.x · Cited by 73
Chun, T.-Y., Gregg, D., Sarkar, D. K., & Gorski, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2325 · Cited by 73
Celik, L., Lund, J. D. D., & Schiøtt, B. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800278d · Cited by 75
DNA‐Controlled Bivalent Presentation of Ligands for the Estrogen Receptor
Abendroth, F., Bujotzek, A., Shan, M., Haag, R., Weber, M., & Seitz, O. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101655 · Cited by 75
Gennari, L., Merlotti, D., & Nuti, R. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s6083 · Cited by 80
Survey of public domain software for docking simulations and virtual screening
Biesiada, J., Porollo, A., Velayutham, P., Kouril, M., & Meller, J. (2011) · Human Genomics · doi:10.1186/1479-7364-5-5-497 · Cited by 75
“The importance of induced fit in the binding of oestrogens to ERs, 45 inherent limitations of scoring functions used by docking programs along with other factors are likely to contribute to the difficulties in virtual screening for candidate inhibitors of ERs and pose limitations for the prediction of oestrogenicity.”
BackgroundHerdick, M., Steinmeyer, A., & Carlberg, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910000199 · Cited by 75
Gee, A. C., & Katzenellenbogen, J. A. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.3.0602 · Cited by 77
Jacobson, K. A., Kim, Y. C., Wildman, S. S. P., Mohanram, A., Harden, T. K., Boyer, J. L., King, B. F., & Burnstock, G. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980183o · Cited by 75
On the toxicity of phenols to fast growing cells. A QSAR model for a radical-based toxicity
Selassie, C. D., Shusterman, A. J., Kapur, S., Verma, R. P., Zhang, L., & Hansch, C. H. (1999) · Journal of the Chemical Society Perkin Transactions 2 · doi:10.1039/a905764a · Cited by 75
van den Bemd, G.-J. C. M., Kuiper, G. G. J. M., Pols, H. A. P., & van Leeuwen, J. P. T. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0864 · Cited by 75
Fuller, P. J., Yang, J., & Young, M. J. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0060 · Cited by 74
Regulation of estrogen receptor beta activity and implications in health and disease
Swedenborg, E., Power, K. A., Cai, W., Pongratz, I., & Rüegg, J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0118-z · Cited by 74
Design of thyroid hormone receptor antagonists from first principles
Webb, P., Nguyen, N.-H., Chiellini, G., Yoshihara, H. A. I., Lima, S. T. D. C., Apriletti, J. W., Ribeiro, R. C. J., Marimuthu, A., West, B. L., Goede, P., et al. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00270-4 · Cited by 74
Kojetin, D. J., Burris, T. P., Jensen, E. V., & Khan, S. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0281 · Cited by 75
Baker, M. E., & Lathe, R. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.07.001 · Cited by 74
Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones
McDevitt, R. E., Malamas, M. S., Manas, E. S., Unwalla, R. J., Xu, Z. B., Miller, C. P., & Harris, H. A. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.013 · Cited by 74
Pearce, S. T., Liu, H., & Jordan, V. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211129200 · Cited by 74
Shi, L. M., Tong, W., Fang, H., Xie, Q., Hong, H., Perkins, R., Wu, J., Tu§, M., Blair, R. M., Branham, W. S., et al. (2002) · SAR and QSAR in environmental research · doi:10.1080/10629360290002235 · Cited by 74
“The precise overlapping of the A-rings of crystal structures for ER-estradiol, ER-raloxifene, ER-DES and ER4-hydroxytamoxifen [14,15], as shown in Fig.”
BackgroundMethodMiyashita, M., Shimada, T., Miyagawa, H., & Akamatsu, M. (2005) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-004-2952-z · Cited by 74
Oestrogen and progestin responses in human endometrium
Punyadeera, C., VERBOST, P. M., & Groothuis, P. G. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00061-x · Cited by 74
Greytak, S. R., & Callard, G. V. (2006) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2006.07.017 · Cited by 74
Farboud, B., Hauksdottir, H., Wu, Y., & Privalsky, M. L. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.8.2844-2858.2003 · Cited by 62
Structural Determinants of Aldosterone Binding Selectivity in the Mineralocorticoid Receptor
Rogerson, F. M., Dimopoulos, N., Sluka, P., Chu, S., Curtis, A. J., & Fuller, P. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36305 · Cited by 66
Ozono, K., Saito, M., Miura, D., Michigami, T., Nakajima, S., & Ishizuka, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32376 · Cited by 74
Endothelial estrogen receptor isoforms and cardiovascular disease
Kim, K. H., Young, B. D., & Bender, J. R. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.02.001 · Cited by 73
“In our transmembrane orientation model, Glu353 and helix3 are available within the ectodomain, whereas helix 6 is not, making the formation of the polar cavity, described above, for E2 binding unlikely.”
Allosteric Controls of Nuclear Receptor Function in the Regulation of Transcription
Billas, I. M. L., & Moras, D. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.03.017 · Cited by 73
“Later, the structures of the homodimeric ERα in its liganded form showed a similar mode of homodimeric association.(21,22) Subsequently, the crystal structures of RXR/RAR(23) and RXR/ PPAR(24) heterodimers revealed the similarity of the heterodimer interfaces with those of RXR and ER and strongly suggested the general…”
BackgroundTargeting the Estrogen Receptor using Steroid–Therapeutic Drug Conjugates (Hybrids)
Dao, K.-L., & Hanson, R. N. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300378e · Cited by 73
m-Carborane bisphenol structure as a pharmacophore for selective estrogen receptor modulators
Ogawa, T., Ohta, K., Yoshimi, T., Yamazaki, H., Suzuki, T., Ohta, S., & Endo, Y. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.032 · Cited by 73
McDonald, S. M., Brive, L., Agus, D. B., Scher, H. I., & Ely, K. R. (2000) · PubMed · Cited by 73
Lazennec, G., Alcorn, J. L., & Katzenellenbogen, B. S. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.6.0318 · Cited by 73
“formation into a transcriptionally active state (4, 16).”
BackgroundIdentification of a New Hormone-Binding Site on the Surface of Thyroid Hormone Receptor
Souza, P. C. T., Puhl, A. C., Martínez, L., Aparício, R., Nascimento, A. S., Figueira, A. C. M., Nguyen, P. T., Webb, P., Skaf, M. S., & Polikarpov, I. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1359 · Cited by 72
“F domain is an extension to the C terminus of H12 present in some of the NRs, with an unknown functional role.”
BackgroundXenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective
Wallace, B. D., & Redinbo, M. R. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.740049 · Cited by 73
“Agonists, such as endogenous ligands and other synthetic mimics, bind to the LBD of NRs and lead to upregulation of gene expression, whereas antagonism works to competitively block agonist binding and prevents gene induction (Brzozowski et al., 1997).”
Feng, Q., & O'Malley, B. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.008 · Cited by 59
“The carboxyl-terminal LBD contains 12 alpha helices (H1 to H12) which form alpha helical sandwich conformation [10].”
BackgroundThe use of raloxifenein osteoporosis treatment
D’Amelio, P., & Isaia, G. C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.782002 · Cited by 72
“This lead to differential transcriptional effects [19,20].”
Ray, D. W. (1999) · Molecular Endocrinology · doi:10.1210/me.13.11.1855 · Cited by 62
Daucane Phytoestrogens: A Structure−Activity Study
Appendino, G., Spagliardi, P., Cravotto, G., Pocock, V., & Milligan, S. R. (2002) · Journal of Natural Products · doi:10.1021/np0201671 · Cited by 72
Hellal-Levy, C. (2000) · Molecular Endocrinology · doi:10.1210/me.14.8.1210 · Cited by 63
Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen
Ariazi, E. A., Leitão, A., Oprea, T. I., Chen, B., Louis, T., Bertucci, A. M., Sharma, C. G. N., Gill, S. D., Kim, H. R., Shupp, H. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0312 · Cited by 72
“The receptor structures were filled with water because ERa (38) and AR crystal structures (39) indicate that specific stable hydrogen bond (H-bond) networks form among particular water molecules, ligands, and amino acid side chains.”
BackgroundNFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms
Frasor, J. M., El-Shennawy, L., Stender, J. D., & Kastrati, I. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.09.013 · Cited by 72
“Upon binding to ER, tamoxifen induces a protein conformation that allows ER to interact with corepressors, such as NCoR1 (Nuclear Receptor Corepressor 1), which leads to the formation of a repressive complex containing histone deacetylases and other epigenetic regulators (Brzozowski et al., 1997).”
Diano, N., Grano, V., Fraconte, L., Caputo, P., RICUPITO, A., Attanasio, A., Bianco, M., Bencivenga, U., Rossi, S., Manco, I., et al. (2006) · Applied Catalysis B: Environmental · doi:10.1016/j.apcatb.2006.07.004 · Cited by 71
Bioactivation of Selective Estrogen Receptor Modulators (SERMs)
Dowers, T. S., Qin, Z., Thatcher, G. R. J., & Bolton, J. L. (2006) · Chemical Research in Toxicology · doi:10.1021/tx060126v · Cited by 72
Full antagonism of the estrogen receptor without a prototypical ligand side chain
Srinivasan, S., Nwachukwu, J. C., Bruno, N. E., Dharmarajan, V., Goswami, D., Kastrati, I., Novick, S., Nowak, J., Cavett, V., Zhou, H.-B., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2236 · Cited by 63
Pavlin, M., Spinello, A., Pennati, M., Zaffaroni, N., Gobbi, S., Bisi, A., Colombo, G., & Magistrato, A. (2018) · Scientific Reports · doi:10.1038/s41598-017-17364-4 · Cited by 71
Delineation of a unique protein–protein interaction site on the surface of the estrogen receptor
Kong, E. H., Heldring, N., Gustafsson, J.-Α., Treuter, E., Hubbard, R. E., & Pike, A. C. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407189102 · Cited by 71
Self-citationThe 2.0 Å crystal structure of the ERα ligand‐binding domain complexed with lasofoxifene
Vajdos, F. F., Hoth, L. R., Geoghegan, K. F., Simons, S. P., LeMotte, P. K., Danley, D. E., Ammirati, M. J., & Pandit, J. (2007) · Protein Science · doi:10.1110/ps.062729207 · Cited by 71
“A notable exception is the SERM raloxifene (Brzozowski et al. 1997), which, presumably because of its five-membered 900 Protein Science, vol. 16 heterocycle core (benzothiophene), directs its phenolic substituent along an altered trajectory, relative to other SERMS, while maintaining approximate…”
BackgroundInfluentialPugazhendhi, D., Watson, K. A., Mills, S., Botting, N., Pope, G. S., & Darbre, P. D. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0384 · Cited by 63
“Dotted arrows indicate the orientation of binding of 17b-oestradiol (Brzozowski et al. 1997) and genistein (Manas et al.”
BackgroundThe Role of Coactivators in Steroid Hormone Action
Bevan, C. L., & Parker, M. G. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4719 · Cited by 72
Edsall, R., Harris, H. A., Manas, E. S., & Mewshaw, R. E. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00303-1 · Cited by 71
Elucidation of the molecular mechanism of action of selective estrogen receptor modulators
McDonnell, D. P., Wijayaratne, A. L., Chang, C., & Norris, J. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02221-4 · Cited by 71
Phytoestrogens in postmenopausal indications: A theoretical perspective
Sunita, P., & Pattanayak, S. P. (2011) · Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy review · doi:10.4103/0973-7847.79098 · Cited by 70
“[11] Molecular modeling studies show the 4-hydroxyl on the B ring of isoflavones to be the binding site for the ER.”
BackgroundInfluentialIntharuksa, A., Arunotayanun, W., Takuathung, M. N., Chaichit, S., Prasansuklab, A., Chaikhong, K., Sirichanchuen, B., Chupradit, S., & Koonrungsesomboon, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146973 · Cited by 72
“In addition, the ligand-binding pocket of ER β is approximately 20% smaller than that of ER α , which may contribute to differences in ligand selectivity and pharmacological behavior [89,90].”
The molecular determinants of estrogen receptor pharmacology
McDonnell, D. P. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.03.006 · Cited by 69
“Using protein crystallography and other techniques, which enable receptor structure to be assessed, it has been shown that the structure of ER is differentially affected by the nature of the bound ligand [14–16].”
BackgroundHit Identification and Binding Mode Predictions by Rigorous Free Energy Simulations
Michel, J., & Essex, J. W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800524s · Cited by 70
Liu, X., Nam, J., Song, Y. S., Viswanath, A. N. I., Pae, A. N., Kil, Y., Kim, H., Park, J. H., Seo, E. K., & Chang, M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.01.029 · Cited by 70
Rodríguez‐Fuentes, G., Sandoval-Gío, J. J., Arroyo-Silva, A., Noreña‐Barroso, E., Escalante-Herrera, K. S., & Olvera-Espinosa, F. (2015) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2015.01.033 · Cited by 70
“ER are the link between E2, gene expression and the chain of mechanisms leading to protein synthesis (Brzozowski et al., 1997).”
BackgroundEstrogenic Activity of Diarylheptanoids from Curcuma comosa Roxb. Requires Metabolic Activation
Winuthayanon, W., Suksen, K., Boonchird, C., Chuncharunee, A., Ponglikitmongkol, M., Suksamrarn, A., & Piyachaturawat, P. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf802702c · Cited by 70
Charmandari, E., Kino, T., Ichijo, T., Zachman, K., Alatsatianos, A., & Chrousos, G. P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1893 · Cited by 63
Lee, S., & Barron, M. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169607 · Cited by 72
Dynamic assembly and activation of estrogen receptor α enhancers through coregulator switching
Murakami, S., Nagari, A., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.302182.117 · Cited by 70
“Furthermore, our results with the selective gain-of-function ERα mutant ERαΔH12-PID, which recruits p300 to a transcriptionally impaired ERα, suggest that p300 recruitment is sufficient for enhancer formation at ERα-binding sites (Fig.”
MethodInfluentialPascussi, J., Gerbal‐Chaloin, S., Drocourt, L., Assénat, E., Larrey, D. G., Pichard‐Garcia, L., Vilarem, M., & Maurel, P. (2004) · Xenobiotica · doi:10.1080/00498250412331285454 · Cited by 72
“The recruitment of coactivators is made through the helix 12 region (AF-2) of nuclear receptors (Brzozowski et al. 1997, Bourguet et al. 2000).”
BackgroundLuconi, M., Bonaccorsi, L., Forti, G., & Baldi, E. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00416-6 · Cited by 70
Estrogen receptor α and estrogen receptor-related receptor α1 compete for binding and coactivator
Zhang, Z., & Teng, C. T. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00372-5 · Cited by 70
Giwercman, A., Kledal, T. N., Schwartz, M., Giwercman, Y. L., Leffers, H. C. B., Zazzi, H., Wedell, A., & Skakkebæk, N. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6626 · Cited by 71
Schafer, J. M., Liu, H., Tonetti, D. A., & Jordan, V. C. (1999) · PubMed · Cited by 70
Schaufele, F., Chang, C., Liu, W., Baxter, J. D., Nordeen, S. K., Wan, Y., Day, R. N., & McDonnell, D. P. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.12.0572 · Cited by 70
“The ligand specificity and temporal characteristics of intranuclear recruitment of ERa with each ligand indicated that, in the cellular environment, distinct conformations of ER are formed in response to E2 and each SERM (7, 10).”
BackgroundMethodInfluentialSelective Estrogen Modulators as an Anticancer Tool:
Sengupta, S., & Jordan, V. C. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78818-0_13 · Cited by 69
Explainable Deep Relational Networks for Predicting Compound-Protein Affinities and Contacts
Karimi, M., Wu, D., Wang, Z., & Shen, Y. (2019) · doi:10.1101/2019.12.28.890103 · Cited by 64
Explainable Deep Relational Networks for Predicting Compound–Protein Affinities and Contacts
Karimi, M., Wu, D., Wang, Z., & Shen, Y. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00866 · Cited by 64
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.